Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Personalized Medicine for COVID-19
share announcement

Personalized Medicine for COVID-19

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Epidemiology".

Deadline for manuscript submissions: 20 September 2024 | Viewed by 1622

Special Issue Editors

Dr. Cleo Anastassopoulou

E-Mail Website
Guest Editor
Department of Microbiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Interests: human genetics and COVID-19 symptoms and severity; molecular evolution of SARS-CoV-2; reinfections; vaccines and anti-virals; long COVID-19; SARS-CoV-2 ecology and host-virus interactions; ethical issues in infectious diseases
Prof. Dr. George P. Patrinos

E-Mail Website
Guest Editor
1. Laboratory of Pharmacogenomics and Individualized Therapy, Department of Pharmacy, School of Health Sciences, University of Patras, University Campus, GR-26504 Rion, Greece
2. Department of Genetics and Genomics, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain P.O. Box 15551, United Arab Emirates
3. Clinical Bioinformatics Unit, Department of Pathology, School of Medicine and Health Sciences, Erasmus University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
Interests: pharmacogenomics; personalized therapeutics; clinical care; clinical implementation; clinical studies; pharmacogenomic testing; health technoloigy assessment; regulatory guidance
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Personalized medicine is progressively gaining momentum in modern healthcare in lieu of the traditional “one-size-fits-all” approach. Recent technological advances, particularly in genomic sequencing, have contributed significantly to this end. The impressive heterogeneity of clinical manifestations of infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and potential long-term consequences of coronavirus disease 2019 (COVID-19), showcase the likely advantages of applying personalized medicine for COVID-19. However, despite the “COVIDation” of medicine, very few studies have been published to date to address the issue. The articles that will be published pertain to, but may not be limited to, the interplay of host and viral factors in the following topics:

  • COVID-19 severity
  • Long-COVID symptoms and severity
  • Response and duration of protection of COVID-19 vaccines
  • Response to therapy and development of resistance to anti-virals
  • Ethical implications of applying precision medicine for COVID-19

Dr. Cleo Anastassopoulou
Prof. Dr. George P. Patrinos
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • COVID-19 severity
  • long-COVID symptoms and severity
  • response and duration of protection of COVID-19 vaccines
  • response to therapy and development of resistance to anti-virals
  • ethical implications of applying precision medicine for COVID-19

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 2681 KiB  
Article
Delta Variant in the COVID-19 Pandemic: A Comparative Study on Clinical Outcomes Based on Vaccination Status
by Damiana-Maria Vulturar, Liviu-Ștefan Moacă, Maria Adriana Neag, Andrei-Otto Mitre, Teodora-Gabriela Alexescu, Diana Gherman, Iulia Făgărășan, Ioana Maria Chețan, Claudia Diana Gherman, Oana-Elena Melinte, Antigona Carmen Trofor and Doina-Adina Todea
J. Pers. Med. 2024, 14(4), 358; https://doi.org/10.3390/jpm14040358 - 28 Mar 2024
Viewed by 567
Abstract
Background: As the global battle against the COVID-19 pandemic endures, the spread of the Delta variant has introduced nuanced challenges, prompting a nuanced examination. Materials and Methods: We performed a multilevel logistic regression analysis encompassing 197 patients, comprising 44 vaccinated individuals (V group) [...] Read more.
Background: As the global battle against the COVID-19 pandemic endures, the spread of the Delta variant has introduced nuanced challenges, prompting a nuanced examination. Materials and Methods: We performed a multilevel logistic regression analysis encompassing 197 patients, comprising 44 vaccinated individuals (V group) and 153 unvaccinated counterparts (UV). These patients, afflicted with the Delta variant of SARS-CoV-2, were hospitalized between October 2021 and February 2022 at the COVID-19 department of a University Centre in Cluj-Napoca, Romania. We compared patient characteristics, CT lung involvement, Padua score, oxygen saturation (O2 saturation), ventilation requirements, dynamics of arterial blood gas (ABG) parameters, ICU admission rates, and mortality rates between the two groups. Results: The UV group exhibited a statistically significant (p < 0.05) proclivity toward developing a more severe form of infection, marked by elevated rates of lung involvement, oxygen requirement, ICU admission, and mortality. Conclusion: Our findings underscore the substantial efficacy of the vaccine in diminishing the incidence of severe disease, lowering the rates of ICU admissions, and mitigating mortality among hospitalized patients. Full article
(This article belongs to the Special Issue Personalized Medicine for COVID-19)
►▼ Show Figures

Figure 1

Review

Jump to: Research

13 pages, 766 KiB  
Review
Investigating ABO Blood Groups and Secretor Status in Relation to SARS-CoV-2 Infection and COVID-19 Severity
by Stefanos Ferous, Nikolaos Siafakas, Fotini Boufidou, George P. Patrinos, Athanasios Tsakris and Cleo Anastassopoulou
J. Pers. Med. 2024, 14(4), 346; https://doi.org/10.3390/jpm14040346 - 26 Mar 2024
Viewed by 501
Abstract
The ABO blood groups, Lewis antigens, and secretor systems are important components of transfusion medicine. These interconnected systems have been also shown to be associated with differing susceptibility to bacterial and viral infections, likely as the result of selection over the course of [...] Read more.
The ABO blood groups, Lewis antigens, and secretor systems are important components of transfusion medicine. These interconnected systems have been also shown to be associated with differing susceptibility to bacterial and viral infections, likely as the result of selection over the course of evolution and the constant tug of war between humans and infectious microbes. This comprehensive narrative review aimed to explore the literature and to present the current state of knowledge on reported associations of the ABO, Lewis, and secretor blood groups with SARS-CoV-2 infection and COVID-19 severity. Our main finding was that the A blood group may be associated with increased susceptibility to SARS-CoV-2 infection, and possibly also with increased disease severity and overall mortality. The proposed pathophysiological pathways explaining this potential association include antibody-mediated mechanisms and increased thrombotic risk amongst blood group A individuals, in addition to altered inflammatory cytokine expression profiles. Preliminary evidence does not support the association between ABO blood groups and COVID-19 vaccine response, or the risk of developing long COVID. Even though the emergency state of the pandemic is over, further research is needed especially in this area since tens of millions of people worldwide suffer from lingering COVID-19 symptoms. Full article
(This article belongs to the Special Issue Personalized Medicine for COVID-19)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop